News

A class of therapies called PDE4 inhibitors, which are approved to manage certain inflammatory diseases, may help boost the functionality of the protein whose defect causes cystic fibrosis (CF), according to a new study. Results also suggest that some available CF treatments may be effective in a broader array…

Taking Kaftrio, a combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., for up to 24 weeks can make signs of inflammation go down in people with cystic fibrosis (CF), and help get rid of Pseudomonas aeruginosa bacteria. That’s according to data from a…

First Wave BioPharma has completed patient screening for the Phase 2 SPAN clinical trial of a new formulation of adrulipase to treat exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. The trial (NCT05719311) will be conducted at three sites in Florida, Illinois, and Nevada, and include…

A young man with cystic fibrosis (CF) has become the first patient in the U.S. to undergo MRI lung imaging combined with Xenoview, a novel technology by Polarean Imaging for visualizing lung ventilation. The scan, done in a 19-year-old CF patient, took place at the Cincinnati Children’s Hospital…

In babies with cystic fibrosis (CF), the types of bacteria living in the upper airway become more diverse during their first year of life, a new study shows. Findings suggest that clinical variables, including the use of antibiotics, had relatively minor effects on these bacterial changes in CF babies.

Secondhand, or passive, exposure to tobacco smoke led to an additional mean loss of 5% predicted lung function in young cystic fibrosis (CF) patients than in those who were unexposed, a review study shows. Researchers analyzed the results of six studies, which used a clinical test known…

Beyond improving lung function, Orkambi (ivacaftor/lumacaftor) has potent anti-inflammatory benefits that may limit immune-related lung damage in people with cystic fibrosis (CF), according to a real-world study. Researchers found that one year of treatment significantly reduced the levels of pro-inflammatory signaling molecules in the bloodstream and airways of…

Children and adolescents with cystic fibrosis (CF) commonly have procedural anxiety — a sudden and excessive fear of a medical procedure leading to acute stress or avoidance — that’s associated with treatment resistance, according to a recent study. Parents and caregivers reported three out of four children view at…

Reducing the use of supportive therapies after starting Trikafta (elexacaftor/tezacaftor/ivacaftor) didn’t negatively impact health outcomes among cystic fibrosis (CF) patients, according to a recent study. Guided by a de-escalation algorithm for safely stopping supportive therapies, patients were able to cut back on such treatments by 50% on average,…

The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for children with cystic fibrosis (CF) as young as one month old, who have at least one gating mutation in their CFTR gene that is responsive to the oral treatment. The agency’s approval was supported by data…